

PRODUCT INFORMATION

Common Name	AiRuiKa;Carbarizumab;Carrizumab;HR-301210;HR301210;INCSHR-1210;INCSHR1210;SHR1210;HSR1210;HSR-1210
Conjugate	Unconjugated
Synonyms	PD1;PD-1;CD279;SLEB2;hPD-1;hPD-I;hSLE1
Applications	N/A
Endotoxin	Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Recommended Dilutions	N/A
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	N/A
IgG type	IgG4
Reactivity	Human
Target	PD-1
Uniprot ID	Q15116
Description	Anti-PD-1(camrelizumab biosimilar) IgG4 mAb
Delivery	4-6 weeks
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Sterility	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μm) prior to use.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only

